Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Apr 23;44(1):77–90. doi: 10.3892/or.2020.7593

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright: © Wang et al.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

Figure 7. — Kaplan-Meier curves depicting OS according to DJ-1 expression and adjuvant chemotherapy. (A) Patients with low DJ-1 expression and who received LFP-based chemotherapy (oxaliplatin, 5-FU and tetrahydrofolate) had a prolonged survival time (P=0.011). (B) Patients with high DJ-1 expression did not benefit from LFP-based chemotherapy (P>0.05). (C) LV-DJ-1, LV-DJ-1-ctrl, LV-DJ-1-RNAi and LV-DJ-1-RNAi-ctrl cell lines were validated by western blot analysis. (D) In addition, the association between DJ-1 expression and chemosensitivity was investigated in vitro. A drug which contains 5-FU (25 µg/ml) and L-OHP (20 µg/ml) was used to act on LV-DJ-1, LV-DJ-1-ctrl, LV-DJ-1-RNAi and LV-DJ-1-RNAi-ctrl cell lines. The inhibition rate was determined using CCK-8 assay. The results indicate that the inhibition rate in the LV-DJ-1-RNAi group was significantly higher when compared with that in LV-DJ-1-RNAi-ctrl group (**P<0.01); however, the inhibition rate in the LV-DJ-1 group was not statistically significant compared with that in the control group (P>0.05). OS, overall survival.